Epitope cuts staff in bid for profitability
This article was originally published in Clinica
Executive Summary
Diagnostics manufacturer Epitope is cutting its workforce by 28% as part of a restructuring programme. This will lead to a $500,000 charge in the third quarter, the company warns, but will result in cost savings of more than $2 million a year. The move is part of Epitope's plan to focus its business and bring the company to profitability, says CEO Adolph Ferro. "We will now have an organisation that has a lower-cost profile, yet is fully resourced to meet the needs of our customers and match the plans of our medical diagnostics marketing partner, SmithKline Beecham."
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.